Please do your own DD using FA +TA
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL....... n may CTIX go Up........I should also mention not all my plays are winners but go being free...which we all take for granted....and lots gave their lives for it.......GO FREEDOM,
Fletch
Gee........I'm not the best to ask that question.......I've been holding Apple since like 2002 and Face Book since I bought the base at $25......Star Bucks even way longer. I might sell just a little CTIX at $5 if it looks way over bought. With the pipeline CTIX has....... why sell too early?
Fletch
Below Hubble deep field.........Wow, looking so far back in time!
Since the $2.27 low was put in..........the chart says going up.
Too bad your being left behind,
Fletch
Below from Microcap Daily,
Fletch
http://www.microcapdaily.com/soligenix-inc-otcbbsngx-hits-new-highs/112177/
Soligenix Inc (OTCBB:SNGX) Hits New Highs
BY AMY MURPHY ON JULY 1, 2015 MICRO CAP INSIDER, STREET WATCH
Soligenix Inc (OTCBB:SNGX) is holding itself well after the recent move it made to a high of $2.95 a share. This continues the run the stock made recently off its base at $1.
SNGX is a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. SNGX has two distinctive programs under development for melioidosis including SGX943 and SGX101 as well as their novel innate defense regulator technology (SGX942) for the treatment of oral mucositis.
Soligenix Inc (OTCBB:SNGX) Vaccines/BioDefense business segment includes active development programs for RiVaxâ„¢, their ricin toxin vaccine candidate, VeloThraxâ„¢, their anthrax vaccine candidate, OrbeShieldâ„¢, their GI acute radiation syndrome therapeutic candidate. The development vaccine programs incorporates the use of SNGX proprietary heat stabilization platform technology, known as ThermoVaxâ„¢.
Back in November 2014 SNGX signed a stock purchase agreement with Lincoln Park Capital Fund, LLC (LPC), providing an initial investment in Soligenix of $600,000 and the availability of additional periodic investments up to $10.0 million over a 36-month term. At its sole discretion, Soligenix has the right to sell to LPC up to an additional $10.0 million of its common stock. With this flexible financing vehicle, Soligenix should be able to focus on advancing its clinical programs.
Melioidosis is an infectious disease caused by a Gram-negative bacterium, Burkholderia pseudomallei, found in soil and water. It is of public health importance in endemic areas, particularly in Thailand and northern Australia. It exists in acute and chronic forms. Signs and symptoms may include pain in chest, bones, or joints; cough; skin infections, lung nodules and pneumonia.
Often referred to as Whitmore’s disease, Melioidosis is of great public health importance in endemic areas. Once a melioidosis is diagnosed, the disease can be treated with the use of appropriate antibiotics.
Melioidosis was in the news recently after the US Centers for Disease Control and Prevention (CDC) launched on inquiry into melioidosis illness at Tulane National Research Center (TNPRC). This has raised the visibility and awareness of melioidosis among healthcare professionals and the general public.
Current treatments for Melioidosis is insufficient; treatments can reduce mortality rate to 10% for uncomplicated cases, but still up to 80% for cases with bacteraemia or severe sepsis using antibiotics.
SNGX has two distinctive programs for Melioidosis: SGX943 and SGX101; SGX943 is being developed to treat infections and tissue damages, belongs to a new class of compounds called Innate Defense Regulators (IDRs).
The Company has specifically developed SGX943 to target the host response to infection making them broadly applicable to many bacterial infections. Soligenix has been investigating the efficacy of SGX943 against B.pseudomallei infection, the causative agent of melioidosis. B. pseudomallei is a Tier 1 biothreat, a National Institute of Allergy and Infectious Diseases (NIAID) category B priority pathogen and a top 5 priority in the most recent Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Strategy document.
This month SNGX presented at the ASM Biodefense and Emerging Infectious Diseases Meeting, preclinical animal data showing that SGX943 is efficacious in Gram-positive methicillin resistant Staphylococcus aureus (MRSA) infection as well as with other Gram-negative pathogens infection
Soligenix also presented preclinical animal data showing that SGX943, either alone or in combination with antibiotic Doxycycline, was effective to increase survival after Bps infection.
The business segment is supported with up to $57 million in government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA). Additionally, Soligenix has an exclusive worldwide collaboration with Intrexon Corporation XON, -1.38% focused on the joint development of SGX101 for the treatment for melioidosis.
Currently trading at a $34 million market valuation SNGX has transformed itself in recent months from illiquid to one of the top traded stocks on the entire bb’s. The Company is fully funded moving forward with $4.2 million in the treasury although they do have $10 million in short term debt. The excitement on SNGX is all about the two distinctive programs under development for melioidosis including SGX943 and SGX101 and the positive data coming back from the trials. SNGX is a stock to watch.
OK........I'll bite.....you don't use charts.....so.....what do you use?
Fletch
That would be real good......lets hope your right,
Fletch
You post on a couple of those examples I gave. They don't like tickers posted on the board, so look at some 5 year charts,
Fletch
Rainy day here today.......so looking at charts a bit. Some bio-techs have gone from $40 down to .12 or from $4.75 down to .15 another $6.90 down to .23 as equal to a big sell off,
Fletch
We can hope that good news drives us to new highs and uplisting soon,
Fletch
Are you talking about the chart or the space pic? The chart is from SharpCharts and the space pic is from http://hubblesite.org/gallery/album/,
Fletch
Most likely Rochester site is https://www.urmc.rochester.edu/ along with Strong Memorial hospital,
Fletch
Yes, I've had the same happen..........you put a bid in at a support low and it just sits there........lots of taking shares from any and all sellers but for me..........no fill.
That article spelled out just how easy they can bring the price to wherever they want........making money along the way.
Lets hope the SA article makes us move up,
Fletch
Thanks BK for the Leo update.....thanks Drano for the manipulation article......I don't think we are a main short target, as good news could make CTIX very painful.......Others much more profitable and going to zero. I do think we are manipulated some tho........
IMO, we are base building now.......$2.50 support,
Fletch
We may have just filled that gap..........Stockta.com shows 2.70 - 2.75 as the gap. I thought it was 2.67 or 2.68 to 2.75 BWDIK,
Fletch
http://www.stockta.com/cgi-bin/analysis.pl?symb=CTIX&cobrand=&mode=stock